Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs

Guillermo Vasquez(Ionis Pharmaceuticals (United States)), Punit P. Seth(Ionis Pharmaceuticals (United States)), Xue‐hai Liang(Arisan Therapeutics (United States)), Michael E. Østergaard(Ionis Pharmaceuticals (United States)), Audrey Low(Ionis Pharmaceuticals (United States)), Michael T. Migawa(Ionis Pharmaceuticals (United States)), Eric E. Swayze(Ionis Pharmaceuticals (United States)), Jinghua Yu(Tianjin University), Stanley T. Crooke(Stanley Foundation), Thazha P. Prakash(Ionis Pharmaceuticals (United States)), Graeme C. Freestone(Ionis Pharmaceuticals (United States)), Cheryl Li De Hoyos(Ionis Pharmaceuticals (United States))
Nucleic Acids Research
February 3, 2021
10.1093/nar/gkab047
Cited by 47

Related Papers

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
|The Lancet|2010|905
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary<i>N</i>-acetyl galactosamine improves potency 10-fold in mice
|Nucleic Acids Research|2014|594
Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit
|Molecular and Cellular Biology|1998|524
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
|Nucleic Acids Research|2006|461
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant.
|Molecular and Cellular Biology|1994|354